JPWO2020257549A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020257549A5 JPWO2020257549A5 JP2021574927A JP2021574927A JPWO2020257549A5 JP WO2020257549 A5 JPWO2020257549 A5 JP WO2020257549A5 JP 2021574927 A JP2021574927 A JP 2021574927A JP 2021574927 A JP2021574927 A JP 2021574927A JP WO2020257549 A5 JPWO2020257549 A5 JP WO2020257549A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- group
- agents
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 229910018828 PO3H2 Inorganic materials 0.000 claims 9
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 7
- 229910006074 SO2NH2 Inorganic materials 0.000 claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- 125000000565 sulfonamide group Chemical group 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 5
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000003003 spiro group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 4
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 4
- 229910003827 NRaRb Inorganic materials 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 3
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- -1 C 1-4alkoxy Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 230000003510 anti-fibrotic effect Effects 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 239000013059 antihormonal agent Substances 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000003154 papilloma Diseases 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 claims 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000033116 Asbestos intoxication Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010006417 Bronchial carcinoma Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 201000005262 Chondroma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 206010048832 Colon adenoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 201000005171 Cystadenoma Diseases 0.000 claims 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 208000005331 Hepatitis D Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 206010024612 Lipoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025219 Lymphangioma Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 241001631646 Papillomaviridae Species 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 1
- 208000034541 Rare lymphatic malformation Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005678 Rhabdomyoma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000037432 Thymic tumor Diseases 0.000 claims 1
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims 1
- 206010046392 Ureteric cancer Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 206010003441 asbestosis Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 208000002445 cystadenocarcinoma Diseases 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims 1
- 206010016629 fibroma Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000008443 lung non-squamous non-small cell carcinoma Diseases 0.000 claims 1
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
- 208000025402 neoplasm of esophagus Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 201000011682 nervous system cancer Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 208000008798 osteoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 208000004333 pleomorphic adenoma Diseases 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 230000003439 radiotherapeutic effect Effects 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 210000001179 synovial fluid Anatomy 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000009377 thymus cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 208000022271 tubular adenoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 201000011294 ureter cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025123800A JP2025170244A (ja) | 2019-06-20 | 2025-07-24 | Ｐｄ－ｌ１疾患の治療のための化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864002P | 2019-06-20 | 2019-06-20 | |
| US62/864,002 | 2019-06-20 | ||
| PCT/US2020/038586 WO2020257549A2 (en) | 2019-06-20 | 2020-06-19 | Compounds for treatment of pd-l1 diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025123800A Division JP2025170244A (ja) | 2019-06-20 | 2025-07-24 | Ｐｄ－ｌ１疾患の治療のための化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022536845A JP2022536845A (ja) | 2022-08-19 |
| JPWO2020257549A5 true JPWO2020257549A5 (cg-RX-API-DMAC7.html) | 2023-06-14 |
Family
ID=74040685
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021574927A Pending JP2022536845A (ja) | 2019-06-20 | 2020-06-19 | Ｐｄ－ｌ１疾患の治療のための化合物 |
| JP2025123800A Pending JP2025170244A (ja) | 2019-06-20 | 2025-07-24 | Ｐｄ－ｌ１疾患の治療のための化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025123800A Pending JP2025170244A (ja) | 2019-06-20 | 2025-07-24 | Ｐｄ－ｌ１疾患の治療のための化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11485708B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3986392A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022536845A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102841588B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114072135A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020294781B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021023750A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3139242A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL288523A (cg-RX-API-DMAC7.html) |
| MA (1) | MA55325A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021015708A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202112875UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020257549A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2421957B1 (en) | 2009-04-22 | 2020-11-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
| US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
| JP7387616B2 (ja) | 2018-02-22 | 2023-11-28 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１アンタゴニストとしてのインダン－アミン |
| CN114340633B (zh) | 2019-05-15 | 2025-12-30 | 凯莫森特里克斯股份有限公司 | 用于治疗pd-l1疾病的三芳基化合物 |
| CN114206338B (zh) | 2019-07-10 | 2025-12-12 | 凯莫森特里克斯股份有限公司 | 作为pd-l1抑制剂的二氢化茚类 |
| US11713307B2 (en) | 2019-10-16 | 2023-08-01 | Chemocentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases |
| PH12022550877A1 (en) | 2019-10-16 | 2023-03-27 | Chemocentryx Inc | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases |
| WO2021236771A1 (en) | 2020-05-22 | 2021-11-25 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
| EP4274559A4 (en) * | 2021-01-05 | 2024-12-11 | Southern Research Institute | PROGRAMMED DEATH-LIGAND-1 MODULATORS |
| TWI770866B (zh) * | 2021-03-10 | 2022-07-11 | 國立清華大學 | 鹵化物材料及包含該鹵化物材料之光學單元和光電元件 |
| IL309620A (en) * | 2021-07-02 | 2024-02-01 | Ascletis Bioscience Co Ltd | Heterocyclic compounds as immunomodulators of PD-L1 interactions |
| CN119212987A (zh) * | 2021-12-16 | 2024-12-27 | 安力高医药股份有限公司 | 用于靶向pd-l1的方法和组合物 |
| CN115010658B (zh) * | 2022-05-11 | 2023-06-27 | 南方医科大学 | 一种化合物及其制备方法与应用 |
| WO2024088036A1 (zh) * | 2022-10-26 | 2024-05-02 | 西安新通药物研究股份有限公司 | 一种非对称性联苯衍生物及其制备方法与医药用途 |
| JP2025527595A (ja) * | 2022-11-22 | 2025-08-22 | 西安新通薬物研究股▲フン▼有限公司 | 新規二環系ｐｄ－ｌ１阻害剤、その製造方法、及び医薬使用 |
| CN116903489B (zh) * | 2023-07-14 | 2025-09-02 | 北京汉典制药有限公司 | 三联苯类化合物、其制备方法及其应用 |
| WO2025029075A1 (ko) * | 2023-08-01 | 2025-02-06 | (주)아이랩 | Pd-l1 억제제로서 신규한 바이페닐 유도체 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2402317B1 (en) | 2006-03-31 | 2013-07-03 | Novartis AG | DGAT inhibitor |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| CN105705489B (zh) | 2013-09-04 | 2019-04-26 | 百时美施贵宝公司 | 用作免疫调节剂的化合物 |
| PL3041828T3 (pl) | 2013-09-06 | 2018-10-31 | Aurigene Discovery Technologies Limited | Pochodne 1,3,4-oksadiazolu i 1,3,4-tiadiazolu jako immunomodulatory |
| RS57508B1 (sr) | 2013-09-06 | 2018-10-31 | Aurigene Discovery Tech Ltd | 1,2,4-derivati oksadiazola kao imunomodulatori |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| JP6767096B2 (ja) * | 2014-12-11 | 2020-10-14 | リティックス バイオファーマ エイエス | 免疫チェックポイント阻害剤の組み合わせ |
| US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| TW201718581A (zh) | 2015-10-19 | 2017-06-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| CA3005727A1 (en) | 2015-11-19 | 2017-05-26 | Incyte Corporation | Substituted 2-methylbiphenyl-3-yl heterocyclic compounds and pharmaceutical compositions thereof useful as immunomodulators |
| TW201726623A (zh) | 2015-12-17 | 2017-08-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| CR20180374A (es) | 2015-12-22 | 2018-10-16 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| EP3190103A1 (en) | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
| MA44860A (fr) | 2016-05-06 | 2019-03-13 | Incyte Holdings Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| WO2017202277A1 (zh) | 2016-05-23 | 2017-11-30 | 中国医学科学院药物研究所 | 2-羟基-4-(2，3-双取代苄氧基)-5-取代苯甲醛衍生物的制备方法 |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CA3028685A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018005374A1 (en) | 2016-06-27 | 2018-01-04 | Chemocentryx, Inc. | Immunomodulator compounds |
| KR102538999B1 (ko) * | 2016-06-29 | 2023-05-31 | 유니버시떼 드 몬트리얼 | 비아릴메틸 헤테로사이클 |
| AU2017294231B2 (en) | 2016-07-05 | 2021-09-09 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof |
| JP7168551B2 (ja) | 2016-07-08 | 2022-11-09 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤として有用な１，３－ジヒドロキシフェニル誘導体 |
| WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| US10144706B2 (en) | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| TW201823199A (zh) | 2016-09-02 | 2018-07-01 | 美商北極星藥品公司 | 免疫檢查點抑制劑、組成物及其方法 |
| JP7106572B2 (ja) | 2016-12-20 | 2022-07-26 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤として有用な化合物 |
| JP7303108B2 (ja) | 2016-12-22 | 2023-07-04 | インサイト・コーポレイション | 免疫調節剤としての二環式複素芳香環化合物 |
| SG10202106743QA (en) | 2016-12-22 | 2021-08-30 | Incyte Corp | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
| US20180177784A1 (en) * | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CR20190318A (es) | 2016-12-22 | 2019-10-21 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| US10654815B2 (en) | 2016-12-29 | 2020-05-19 | Shenzhen Chipscreen Biosciences Co., Ltd. | Urea compound and preparation method and application thereof |
| CN108395443B (zh) | 2017-02-04 | 2021-05-04 | 广州丹康医药生物有限公司 | 抑制程序性死亡受体配体1的环状化合物及其用途 |
| EP3601258B1 (en) | 2017-03-27 | 2023-08-30 | Bristol-Myers Squibb Company | Substituted isoquionline derivatives as immunomudulators |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| WO2018196768A1 (zh) | 2017-04-26 | 2018-11-01 | 南京圣和药业股份有限公司 | 作为pd-l1抑制剂的杂环类化合物 |
| CN108863963B (zh) | 2017-05-08 | 2022-05-27 | 南京圣和药物研发有限公司 | 作为pd-l1抑制剂的杂环类化合物 |
| WO2019034172A1 (zh) | 2017-08-18 | 2019-02-21 | 上海轶诺药业有限公司 | 一种具有pd-l1抑制活性的化合物、其制备方法及用途 |
| JP7257393B2 (ja) | 2017-10-03 | 2023-04-13 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤 |
| CN109665968B (zh) | 2017-10-16 | 2022-02-22 | 四川科伦博泰生物医药股份有限公司 | 并环化合物及其制备方法和用途 |
| CN109678796B (zh) | 2017-10-19 | 2023-01-10 | 上海长森药业有限公司 | Pd-1/pd-l1小分子抑制剂及其制备方法和用途 |
| CN109721527B (zh) | 2017-10-27 | 2024-03-12 | 广州丹康医药生物有限公司 | 一种新型抗pd-l1化合物、其应用及含其的组合物 |
| WO2019087214A1 (en) | 2017-11-06 | 2019-05-09 | Jubilant Biosys Limited | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
| CN109956898B (zh) | 2017-12-22 | 2021-03-26 | 上海海雁医药科技有限公司 | 免疫调节剂及其制法与医药上的用途 |
| SG11202005962YA (en) | 2017-12-29 | 2020-07-29 | Guangzhou Maxinovel Pharmaceuticals Co Ltd | Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application |
| US11414418B2 (en) | 2018-01-23 | 2022-08-16 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| ES3035608T3 (en) | 2018-02-05 | 2025-09-05 | Abbisko Therapeutics Co Ltd | Biaryl derivatives and their pharmaceutical application for the treatment of pd-1/pd-l1 signal pathway-mediated diseases |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| WO2019169123A1 (en) | 2018-03-01 | 2019-09-06 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| SG11202008950PA (en) | 2018-03-13 | 2020-10-29 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| WO2019174533A1 (zh) | 2018-03-13 | 2019-09-19 | 广东东阳光药业有限公司 | Pd-1/pd-l1类小分子抑制剂及其在药物中的应用 |
| EP4212529B1 (en) | 2018-03-30 | 2025-01-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20210040118A1 (en) | 2018-04-03 | 2021-02-11 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| CA3093130C (en) * | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| EP4520328A3 (en) | 2018-05-11 | 2025-04-16 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| TWI798463B (zh) | 2018-07-11 | 2023-04-11 | 大陸商上海和譽生物醫藥科技有限公司 | 免疫抑制劑及其製備方法和在藥學上的應用 |
| US20220119411A1 (en) | 2018-07-12 | 2022-04-21 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| TWI809427B (zh) | 2018-07-13 | 2023-07-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| WO2020015717A1 (en) | 2018-07-19 | 2020-01-23 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| US20210269440A1 (en) | 2018-07-19 | 2021-09-02 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| EP3831823A4 (en) | 2018-08-01 | 2022-04-27 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | PREPARATION AND USE OF AN AROMATIC COMPOUND WITH IMMUNEGULATORY FUNCTION |
| CN109336857A (zh) | 2018-11-13 | 2019-02-15 | 南方医科大学 | 一种含取代联苯的黄酮及其应用 |
| CN109438263A (zh) | 2018-11-28 | 2019-03-08 | 南方医科大学 | 一种含取代联苯的萘及其应用 |
| CN109503546A (zh) | 2019-01-10 | 2019-03-22 | 南方医科大学 | 一种间苯二酚二苯甲醚及其应用 |
| CN109776377B (zh) | 2019-02-01 | 2021-08-24 | 沈阳药科大学 | 吲哚啉类化合物及其制备方法和应用 |
| CN109776445B (zh) | 2019-03-28 | 2022-12-06 | 中国药科大学 | 苯并噁二唑类化合物及其制备方法和医药用途 |
| CN114340633B (zh) | 2019-05-15 | 2025-12-30 | 凯莫森特里克斯股份有限公司 | 用于治疗pd-l1疾病的三芳基化合物 |
| CN110200959A (zh) | 2019-05-30 | 2019-09-06 | 天津科技大学 | 一种黄酮类化合物的应用 |
| CN110128415B (zh) | 2019-05-31 | 2022-03-25 | 沈阳药科大学 | 用作免疫调节剂的吲哚啉类化合物及其制备方法 |
-
2020
- 2020-06-19 CA CA3139242A patent/CA3139242A1/en active Pending
- 2020-06-19 EP EP20827461.3A patent/EP3986392A4/en active Pending
- 2020-06-19 BR BR112021023750A patent/BR112021023750A2/pt unknown
- 2020-06-19 AU AU2020294781A patent/AU2020294781B2/en active Active
- 2020-06-19 MX MX2021015708A patent/MX2021015708A/es unknown
- 2020-06-19 SG SG11202112875UA patent/SG11202112875UA/en unknown
- 2020-06-19 WO PCT/US2020/038586 patent/WO2020257549A2/en not_active Ceased
- 2020-06-19 MA MA055325A patent/MA55325A/fr unknown
- 2020-06-19 US US16/905,979 patent/US11485708B2/en active Active
- 2020-06-19 JP JP2021574927A patent/JP2022536845A/ja active Pending
- 2020-06-19 CN CN202080045326.XA patent/CN114072135A/zh active Pending
- 2020-06-19 KR KR1020227001806A patent/KR102841588B1/ko active Active
-
2021
- 2021-11-29 IL IL288523A patent/IL288523A/en unknown
-
2025
- 2025-07-24 JP JP2025123800A patent/JP2025170244A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020257549A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2020232256A5 (cg-RX-API-DMAC7.html) | ||
| JP2018158926A5 (cg-RX-API-DMAC7.html) | ||
| RU2015143717A (ru) | 2-Аминопиримидин-6-оны и аналоги, проявляющие противораковые и антипролиферативные действия | |
| JP2020504716A5 (cg-RX-API-DMAC7.html) | ||
| JP2019527202A5 (cg-RX-API-DMAC7.html) | ||
| JP2011510995A5 (cg-RX-API-DMAC7.html) | ||
| IL271291B2 (en) | History of n2,n4-diphenylpyrimidine-2,4-diamine, a method for their preparation, and a pharmaceutical preparation containing them as an active ingredient for the prevention or treatment of cancer | |
| HRP20221216T1 (hr) | Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1 | |
| RU2011101898A (ru) | Триазолпиридиновые соединения, ингибирующие jak, и способы | |
| CN113316574A (zh) | Shp2抑制剂及其应用 | |
| JP2009526072A5 (cg-RX-API-DMAC7.html) | ||
| RU2017139515A (ru) | Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там | |
| JP2016523973A5 (cg-RX-API-DMAC7.html) | ||
| CN114430740A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2018529739A5 (cg-RX-API-DMAC7.html) | ||
| JP2020521741A5 (cg-RX-API-DMAC7.html) | ||
| RU2014131378A (ru) | Ингибиторы бромдомена | |
| JP2018507877A5 (cg-RX-API-DMAC7.html) | ||
| JP2017505808A5 (cg-RX-API-DMAC7.html) | ||
| JP2018505880A5 (cg-RX-API-DMAC7.html) | ||
| JP2015529235A5 (cg-RX-API-DMAC7.html) | ||
| RU2014153800A (ru) | Соединения 5-азаиндазола и способы их применения | |
| RU2007133111A (ru) | Соединения, ингибирующие raf, и способы | |
| RU2021101430A (ru) | Производные бензимидазола как ингибиторы тирозинкиназ erbb для лечения рака |